PFIZER INC
For the period ended Jun 29, 2025. Filed Aug 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 29, 2025 · Filed Aug 5, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Provision/(Benefit) for Taxes on Income/(Loss)
| Three Months Ended | Six Months Ended | |||||
|---|---|---|---|---|---|---|
| (MILLIONS) | June 29,2025 | June 30,2024 | %Change | June 29,2025 | June 30,2024 | %Change |
| Provision/(benefit) for taxes on income/(loss) | $141 | $(134) | * | $(48) | $159 | * |
| Effective tax rate on continuing operations | 4.6% | 130.2% | (0.8)% | 4.8% | ||
For information about our effective tax rate and the events and circumstances contributing to the changes between periods, as well as details about discrete elements that impacted our tax provisions, see Note 5. See Note 5Ain our 2024 Form 10-K for information on our cash paid for income taxes, net of refunds.
Changes in Tax Laws––Many countries outside the U.S. have enacted legislation for global minimum taxation resulting from the Organization for Economic Co-operation and Development’s (OECD) Base Erosion and Profit Shifting “Pillar 2” project. The EU approved a directive requiring member states to incorporate the OECD provisions into their respective domestic laws, and countries outside the EU have also been enacting the provisions into their domestic law. The provisions are generally effective for Pfizer since 2024, though significant details and guidance around the provisions are still pending. Income tax expense could be impacted as the legislation becomes effective in countries in which we do business, and such impact could be material to our results of operations. We continue to monitor pending OECD guidance and legislation enactment and implementation by individual countries.
On July 4, 2025, the OBBBA was enacted into law in the U.S. The OBBBA includes significant tax provisions, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act and modifications to the U.S. international tax framework. Among the favorable business provisions are the permanent expensing for domestic R&D costs, permanent bonus depreciation and full expensing of qualified production property. The legislation includes various effective dates, with certain provisions effective in 2025. We expect further guidance may be issued by the U.S. government with respect to certain OBBBA tax provisions. We are still analyzing the OBBBA and assessing its impacts. Our income tax expense could be impacted by the OBBBA, after taking into account any further guidance, and such impact could potentially be material to our results of operations.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.